Deals, Development and Manufacturing

Sanofi Drops Lantus US List Price by 78%, Capping Out-of-Pocket Costs at $35

March 21, 2023

Sanofi intends to cut its US list price for Lantus (insulin glargine injection) by 78% and cap out-of-pocket costs at $35 for all patients with commercial insurance.

BioNTech and OncoC4 to Co-Develop mAb for Solid Tumor Indications

March 21, 2023

BioNTech will receive an exclusive worldwide license from OncoC4 to develop and commercialize its anti-CTLA-4 mAb candidate for solid tumor indications.

Stevanato Group and Recipharm to Collaborate on Pre-fillable Syringes for Soft Mist Inhaler

March 17, 2023

Stevanato Group will support development and production of pre-fillable syringes for use in Recipharm’s soft mist inhalers.

Catalent Licenses Bhami Research Laboratory Technology for Biologics Formulation Development

March 17, 2023

Under a technology licensing agreement with Bhami Research Laboratory, Catalent intends to develop formulations that will allow for the delivery of high-concentration biologics subcutaneously.

Genuv and Celltrion Partner on Development of Novel Therapeutic Antibodies

March 17, 2023

The collaboration between Genuv and Celltrion will utilize Genuv's proprietary mouse platform for antibody discovery.

Pfizer to Acquire Seagen in $43 Billion Blockbuster Deal

March 16, 2023

Pfizer will acquire all outstanding shares of Seagen for a total of $43 billion.

Frontrunner in Microbiome Therapeutics

March 03, 2023

EnteroBiotix is harnessing the power of the microbiome to target an array of diseases.

Feeling the Pinch

March 02, 2023

Soaring energy costs are compounding the challenges currently being faced by the European bio/pharma industry.

AstraZeneca Strikes $1.16 Billion Licensing Deal for Gastric Cancer Candidate

March 01, 2023

AstraZeneca has entered into a global exclusive license agreement with KYM Biosciences for CMG901, which is being investigated as a gastric cancer treatment.

Moderna and Life Edit Therapeutics Enter Gene Editing Collaboration

February 24, 2023

Moderna will leverage Life Edit’s suite of gene editing technologies to advance development of in vivo gene editing therapies.